Over the past decades, medicine has made tremendous progress in delivering new life-saving treatments to patients in need.
Inherent to this are side effects that have frustrated the development of new compounds with great potential or led to withdrawal of already approved drugs from the market. Drug side effects put patient safety at risk, highlighting the need for improved drug safety measures.
ABS Biotechnologies was founded with the mission to provide patients with safer medicines using our stem cell and cardiovascular expertise. Using IP from a world-leading academic laboratory at the University of Cambridge we strive to eradicate drug-induced heart attacks, strokes, high blood pressure, and irregular heart rhythms.
We are expanding access to ethnically diverse induced pluripotent stem cells (iPSCs) to support more inclusive biomedical research. Incorporating diverse iPSCs into biologically relevant human cell models better represents population diversity, enabling researchers to generate findings that are more representative and broadly applicable.
We provide advanced cardiovascular models that more accurately reflect the complexity of the human cardiovascular system. These physiologically relevant models enable earlier and more reliable identification of potential safety risks, reducing the likelihood that harmful compounds progress to clinical trials or ultimately reach patients.
Our screening platform supports better decision-making throughout the drug development process. By providing more predictive and representative preclinical testing, we help reduce the risk of discarding promising drug candidates due to the limitations of conventional models, allowing pharmaceutical developers to focus resources on the most promising compounds.
ABS Biotechnologies is committed to measuring and reducing its carbon emissions.
As a company, we will be introducing corporate sustainability principles in our business strategy and operations, which is an essential component in both creating long-term value and achieving our mission of contributing to a safer and healthier world.
Furthermore, ABS Biotechnologies has committed to the 3R model (reduction, refinement and replacement) for avoidance of animal use in research.
New treatments have to be safe.
